LENZ Therapeutics (LENZ) Stock Overview
Operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LENZ Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
LENZ Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.29 |
| 52 Week High | US$50.40 |
| 52 Week Low | US$8.25 |
| Beta | 2.29 |
| 1 Month Change | -22.19% |
| 3 Month Change | -37.53% |
| 1 Year Change | -49.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.65% |
Recent News & Updates
Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers
Mar 29
LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade)
Mar 27LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 27Recent updates
Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers
Mar 29LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade)
Mar 27LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 27Here's Why We're Not At All Concerned With LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn Situation
Dec 13Earnings Beat: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 08LENZ Therapeutics Stock Is Attractive Before PDUFA
Mar 27Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth
Jan 01LENZ Therapeutics: Time For A Pause
Nov 27LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
Aug 30Shareholder Returns
| LENZ | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.9% | 0.7% | 3.4% |
| 1Y | -49.9% | 43.5% | 29.7% |
Return vs Industry: LENZ underperformed the US Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: LENZ underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| LENZ volatility | |
|---|---|
| LENZ Average Weekly Movement | 11.4% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: LENZ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LENZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 152 | Eef Schimmelpennink | www.lenz-tx.com |
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021.
LENZ Therapeutics, Inc. Fundamentals Summary
| LENZ fundamental statistics | |
|---|---|
| Market cap | US$296.30m |
| Earnings (TTM) | -US$82.13m |
| Revenue (TTM) | US$19.09m |
Is LENZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LENZ income statement (TTM) | |
|---|---|
| Revenue | US$19.09m |
| Cost of Revenue | US$418.00k |
| Gross Profit | US$18.67m |
| Other Expenses | US$100.80m |
| Earnings | -US$82.13m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.62 |
| Gross Margin | 97.81% |
| Net Profit Margin | -430.25% |
| Debt/Equity Ratio | 0% |
How did LENZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 11:38 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LENZ Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Matthew Caufield | H.C. Wainwright & Co. |